Dublin, Sept. 25, 2024 (GLOBE NEWSWIRE) -- The "PCR and Realtime PCR Testing Global Market Opportunities and Strategies to 2033" report has been added to ResearchAndMarkets.com's offering.
The global PCR (Polymerase Chain Reaction) and realtime PCR testing market, having reached a valuation of nearly $10.1 billion in 2023, is anticipated to experience a robust compound annual growth rate from 2023 to 2028 and further strong growth through to 2033. Projections see the market escalating to a substantial $14.3 billion by 2028 and subsequently achieving $20.8 billion by 2033. This notable expansion is attributed to various factors including a global surge in healthcare expenditure, heightened R&D activities, and an increasing prevalence of chronic diseases which necessitate sophisticated diagnostic capabilities.
Among the diverse product segments, consumables and reagents continue to maintain the lion's share, representing 61.10% of the total market in 2023. However, it is the software segment which is projected to exhibit the most rapid growth at a CAGR of 8.28% during the 2023-2028 period. When analyzed by technology, quantitative polymerase chain reaction (qPCR) stood as the dominant sector, yet the emergence of digital polymerase chain reaction (dPCR) technology is foreseen to outpace other segments, with the fastest growth rate projected at a CAGR of 9.38% from 2023 to 2028. The largest application of PCR and realtime PCR testing resides within clinical diagnostics, a trend that is expected to progress further, while the end-user segment analysis shows clinical diagnostics labs and hospitals at the forefront, with continued dominance anticipated in the upcoming years.
Geographically, North America currently holds the majority market share, but Asia Pacific and Western Europe are predicted to be the fastest-growing regions in the PCR and realtime PCR testing market. The markets in these regions will grow at CAGRs of 8.76% and 7.59% respectively, followed subsequently by South America and North America.
Despite the market's somewhat fragmented nature with many small players, it has demonstrated a competitive environment where the top ten competitors made up 20.17% of the market share in 2022. The market landscape is defined by continuous innovation and strategic partnerships among key players aiming to enhance their operational capabilities and expand their market presence.
Focusing on unmet healthcare needs through innovative diagnostic solutions is a prevailing trend, alongside investment initiatives intended to drive point-of-care PCR testing evolution. Firms are encouraged to pursue strategic collaborations to leverage market opportunities effectively. Furthermore, organizations are advised to prioritize enhanced RT-PCR diagnostic options as well as develop advanced real-time PCR allergen detection kits, tapping into emerging markets and established economies alike.
Emphasis on clinical diagnostics and life science research, particularly targeting clinical diagnostics labs and hospitals, can potentially create sizable growth prospects for companies within the PCR and realtime PCR testing market space. The market holds significant potential with the expansion of digital and quantitative polymerase chain reaction segments and the awareness of cost-competitive offerings to harness the opportunities present in this evolving landscape.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 327 |
| Forecast Period | 2023 - 2033 |
| Estimated Market Value (USD) in 2023 | $10.1 Billion |
| Forecasted Market Value (USD) by 2033 | $20.8 Billion |
| Compound Annual Growth Rate | 7.4% |
| Regions Covered | Global |
Companies Featured
- F. Hoffmann-La Roche Ltd.
- Danaher Corporation
- General Electric Company
- Becton Dickinson and Company
- Eurofins Scientific SE
- Thermo Fisher Scientific Inc.
- bioMérieux SA
- Bio-Rad Laboratories Inc.
- Abbott Laboratories Ltd.
- Takara Bio Inc.
- Cipla Limited
- Molbio Diagnostics
- Vela Diagnostics
- 3DMed Diagnosticṣ
- Prenetics Limited
- NuHigh Biotechnologies Co. Ltd
- Beijing Applied Biological Technologies Co. Ltd.
- Dirui Industrial Co., Ltd.
- Fapon Biotech Inc.
- Heal Force Bio-meditech Holdings Limited
- Integrated BioSystems Co. Ltd.
- Jiangsu Bioperfectus Technologies Co., Ltd.
- Roche Diagnostics India Pvt Ltd
- Qiagen India Pvt Ltd
- Biocartis
- Bio-Techne India Private Limited
- Kaneka Corporation
- Randox
- Siemens Healthineers AG
- Qiagen N.V.
- QuantuMDx
- BLIRT S.A.
- GeneMe
- Co-Diagnostics, Inc
- Interlabservis
- TestLine Clinical Diagnostics s.r.o.
- Terrasigna
- MatMa Corporation
- DiaSorin SpA
- Innova Medical Group Inc.
- Todos Medical
- Agilent Technologies Inc.
- Sysmex Inostics
- Eppendorf AG
- Anitoa Systems LLC.
- Dickinson and Company
- Beckmen Coulter Inc.
- Cepheid
- Clontech Laboratories
- Fluidigm
- PerkinElmer
- Harvard Bioscience
- Maxim Biotech
- Promega
- Kapa Biosystems
- Rain Dance technologies
- Noor DX
- GE Healthcare
- Draegerwerk AG
- B. Braun Melsungen
- ResMed Inc.
- Smiths Medical
- Chemical, Industrial & Pharmaceutical Laboratories Ltd
For more information about this report visit https://www.researchandmarkets.com/r/y2rkhr
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
